AbbVie, Amgen, and Takeda collaborate using clinical trial data and real-world evidence (RWE) to combat COVID-19

• The partner companies will evaluate the ability of the drugs to reduce or mitigate the severity of acute respiratory distress syndrome (ARDS), which is observed in around 10-15% of COVID-19 patients
• As part of the alliance, members are sharing clinical trial data and RWE, as well as crowd-sourcing early-stage candidates to identify mechanisms or treatments that could be effective against COVID-19
• The joint trial is just the latest in a growing trend of pharmaceutical companies repurposing existing drugs and experimental candidates as potential treatments for COVID-19

Click here to learn more

About SVMPharma

SVMPharma is an innovative strategic consultancy, specialising in Real-World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real-World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.

For more information, please visit www.svmpharma.com and contact us at enquiry@svmpharma.com

ref: OCT2020HM002